ZE50-0134

Phase 1Small molecule

LLomond Therapeutics Holdings, Inc.

ZE50-0134 is one of 101 small molecule programs targeting Chronic Lymphocytic Leukemia. It is currently in Phase 1.

Indications

Total Trials

Active Trials

100

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Lymphocytic LeukemiaRecruiting

Acute Myeloid LeukemiaRecruiting

Chronic Lymphocytic LeukemiaPhase 1

Recruiting

Acute Myeloid LeukemiaPhase 1

Recruiting

Competition

Competitive Landscape

255 competitors in Acute Myeloid Leukemia

#DrugCompanyPhaseTrials

Idamycin

Pfizer

Phase 3

59 2

Novantrone

Pfizer

Phase 3

34 3

Xospata

Astellas

Phase 3

24 4

Fludara

Sanofi

Phase 3

17 5

Cerubidine

EEastern Cooperative Oncology Group

Phase 3

42 6

Vepesid

AAvyxa

Phase 3

52 7

Mylotarg

WWyeth-Lederle Vaccines

Phase 3

38 8

Vanflyta

Daiichi Sankyo

Phase 3

14 9

Neupogen

EEastern Cooperative Oncology Group

Phase 3

31 10

Cerubidine

HHikma Pharmaceuticals LLC

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Recruiting

Acute Myeloid Leukemia

NCT07303660

Q3 2028

Phase 1Recruiting

Chronic Lymphocytic Leukemia

NCT06708897

Clinical

Trials by Indication[1]

Acute Myeloid Leukemia1 trial

A Phase 1b Study of Lonitoclax + Azacitidine (Aza) in Acute Myeloid Leukemia (AML) Patients

Recruiting·LLomond Therapeutics Holdings, Inc.·Phase 1·NCT07303660·66 enrolled

Chronic Lymphocytic Leukemia1 trial

Phase 1 Study of Lonitoclax (ZE50-0134) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), and Select Low-grade Lymphomas

Recruiting·LLomond Therapeutics Holdings, Inc.·Phase 1·NCT06708897·84 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for ZE50-0134. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ZE50-0134 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ZE50-0134. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Lomond Therapeutics Holdings, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: LLomond Therapeutics Holdings, Inc.

ZE50-0134

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q3 2028

Trials by Indication[1]

Acute Myeloid Leukemia1 trial

Chronic Lymphocytic Leukemia1 trial

References

Drug Info

Quick Facts

Related News